“十四五”期间我国企业净增近2000万户，市场监管总局最新发声

Group 1: Market Regulation Achievements - Since the beginning of the 14th Five-Year Plan, the national market regulatory authorities have improved the supervision system for enterprise-related fees, continuously reducing operational costs for businesses. The number of new enterprises increased by 19.99 million, and individual businesses increased by 33.94 million [1][2] - The introduction of the "Fair Competition Review Regulations" has established rigid institutional constraints against issues such as "malicious competition" in investment promotion and administrative monopolies. A total of 4,218 policies that hindered the flow of factors were abolished, and 239 administrative monopoly cases were investigated [1][2] Group 2: Consumer Protection and Efficiency - During the 14th Five-Year Plan, market regulatory authorities handled 89.03 million complaints, recovering economic losses of 21.71 billion yuan for consumers. Consumer associations processed 5.75 million complaints, recovering 5.78 billion yuan [2] - The time required to open a restaurant has been reduced from 37 days to 15 days, and the number of documents required for business information changes has been streamlined from 23 to 6 [2] Group 3: Platform Economy Regulation - The platform economy is undergoing a critical transformation, with the integration of digital technology across industries leading to new growth points but also risks such as algorithm abuse and disorderly competition. Regulatory authorities are balancing innovation encouragement with development regulation [4][5] - Regulatory actions have led to the removal of 4.54 million illegal product listings and the suspension of services for 58,000 online stores. Major cases in the live-streaming e-commerce sector have been addressed [5] Group 4: Pharmaceutical Industry Developments - China's pharmaceutical industry ranks second globally, with 204 innovative drugs and 265 innovative medical devices approved since the beginning of the 14th Five-Year Plan. The number of innovative drugs in development accounts for about 30% of the global total [7][8] - The National Medical Products Administration has implemented dynamic supervision covering the entire drug lifecycle, focusing on key areas such as online sales and clinical trial management [7][8]